A Longitudinal Study Evaluating Molecular Changes Associated With Resistance to First and Third (AZD9291) Generation EGFR TKIs in Patients With EGFR Mutant NSCLC Using "Liquid Biopsy"
Phase of Trial: Phase II
Latest Information Update: 12 Oct 2016
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Pharmacodynamics
- 07 Jun 2017 Biomarkers information updated
- 03 Oct 2016 Status changed from not yet recruiting to recruiting.
- 16 May 2016 New trial record